Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53

被引:5
|
作者
Almazi, Juhura G. [1 ]
Mactier, Swetlana [1 ]
Best, O. Giles [2 ]
Crossett, Ben [1 ]
Mulligan, Stephen P. [1 ,2 ]
Christopherson, Richard I. [1 ]
机构
[1] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia
[2] Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia
关键词
B-lymphoproliferative disorders; Fludarabine; p53; p63; p73; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR; DNA-DAMAGE; APOPTOSIS; EXPRESSION; DEATH; GENE; ISOFORMS; PROTEIN; CANCER;
D O I
10.1002/prca.201200003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Purpose Human Raji cells treated with fludarabine nucleoside (2-FaraA, 3 mu M) undergo apoptosis with accumulation of p53 in the nuclei as multiple phosphorylated isoforms and C-terminal truncated derivatives. Changes induced by 2-FaraA in the levels of p53, p63 and p73 in the nuclear, cytosolic and mitochondrial fractions have been determined in four human B-lymphoid cell lines that are TP53-functional (Raji and IM9) and TP53-mutated (MEC1 and U266). Experimental design The B-lymphoid cell lines were treated with 2-FaraA (3 mu M, 24 h, 48 h) and viability determined. Protein extracts of subcellular fractions from 2-FaraA-treated cells were analysed by 1D and 2D electrophoresis; multiple phosphorylated isoforms and truncated derivatives were identified by Western blots for p53, p63 and p73. Results p53 and p63 were present in all three fractions, while p73 was only detected in nuclei. After treatment with 2-FaraA, nuclear p53, p63 and p73 accumulated as multiple phosphorylated isoforms and truncated derivatives. The association of p63 with mitochondria in human cells is novel. Conclusions and clinical relevance Comprehensive information on the subcellular distributions and responses of p53, p63 and p73 to 2-FaraA provides additional insight into mechanisms for induction of apoptosis in the treatment of B-lymphoproliferative disorders with fludarabine.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [1] From p53 to p63 and p73
    不详
    TRENDS IN GENETICS, 1999, 15 (06) : 222 - 222
  • [2] p63 and p73, the Ancestors of p53
    Doetsch, V.
    Bernassola, F.
    Coutandin, D.
    Candi, E.
    Melino, G.
    COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (09): : a004887
  • [3] From p63 to p53 across p73
    Strano, S
    Rossi, M
    Fontemaggi, G
    Munarriz, E
    Soddu, S
    Sacchi, A
    Blandino, G
    FEBS LETTERS, 2001, 490 (03): : 163 - 170
  • [4] Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines
    Almazi, Juhura G.
    Alomari, Munther
    Belov, Larissa
    Best, O. Giles
    Shen, Yandong
    Graham, Mark E.
    Mulligan, Stephen P.
    Christopherson, Richard I.
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2022, 41 (03): : 314 - 320
  • [5] p53/p63/p73 in the Epidermis in Health and Disease
    Botchkarev, Vladimir A.
    Flores, Elsa R.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2014, 4 (08):
  • [6] P63 and p73: P53 mimics, menaces and more
    Yang, A
    McKeon, F
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2000, 1 (03) : 199 - 207
  • [7] p63 and p73: p53 mimics, menaces and more
    Annie Yang
    Frank McKeon
    Nature Reviews Molecular Cell Biology, 2000, 1 : 199 - 207
  • [8] On the shoulders of giants: p63, p73 and the rise of p53
    Yang, A
    Kaghad, M
    Caput, D
    McKeon, F
    TRENDS IN GENETICS, 2002, 18 (02) : 90 - 95
  • [9] P63 and P73 Activation in Cancers with p53 Mutation
    Cai, Bi-He
    Hsu, Yun-Chien
    Yeh, Fang-Yu
    Lin, Yu-Rou
    Lu, Rui-Yu
    Yu, Si-Jie
    Shaw, Jei-Fu
    Wu, Ming-Han
    Tsai, Yi-Zhen
    Lin, Ying-Chen
    Bai, Zhi-Yu
    Shih, Yu-Chen
    Hsu, Yi-Chiang
    Liao, Ruo-Yu
    Kuo, Wei-Hsin
    Hsu, Chao-Tien
    Lien, Ching-Feng
    Chen, Chia-Chi
    BIOMEDICINES, 2022, 10 (07)
  • [10] Neuronal survival and p73/p63/p53: A family affair
    Jacobs, WB
    Walsh, GS
    Miller, FD
    NEUROSCIENTIST, 2004, 10 (05): : 443 - 455